These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 30144998

  • 1. Effective infliximab therapy for the early regression of coronary artery aneurysm in Kawasaki disease.
    Nagatomo Y, Muneuchi J, Nakashima Y, Nanishi E, Shirozu H, Watanabe M, Uike K, Nagata H, Hirata Y, Yamamura K, Takahashi Y, Okada S, Suzuki Y, Hasegawa S, Ohga S.
    Int J Cardiol; 2018 Nov 15; 271():317-321. PubMed ID: 30144998
    [Abstract] [Full Text] [Related]

  • 2. [Retrospective analysis of infliximab in the treatment of Kawasaki disease].
    Xie LP, Zhao L, Chu C, He L, Liang XC, Sun SN, Zhao QM, Wang F, Cao YY, Lin YX, Zeng ZQ, Wu L, Huang GY, Liu F.
    Zhonghua Er Ke Za Zhi; 2022 Jan 02; 60(1):14-19. PubMed ID: 34986617
    [Abstract] [Full Text] [Related]

  • 3. Treatment Intensification in Patients With Kawasaki Disease and Coronary Aneurysm at Diagnosis.
    Dionne A, Burns JC, Dahdah N, Tremoulet AH, Gauvreau K, de Ferranti SD, Baker AL, Son MB, Gould P, Fournier A, Newburger JW, Friedman KG.
    Pediatrics; 2019 Jun 02; 143(6):. PubMed ID: 31048414
    [Abstract] [Full Text] [Related]

  • 4. Infliximab for intensification of primary therapy for patients with Kawasaki disease and coronary artery aneurysms at diagnosis.
    Miyata K, Bainto EV, Sun X, Jain S, Dummer KB, Burns JC, Tremoulet AH.
    Arch Dis Child; 2023 Oct 02; 108(10):833-838. PubMed ID: 37258054
    [Abstract] [Full Text] [Related]

  • 5. Infliximab is the new kid on the block in Kawasaki disease: a single-centre study over 8 years from North India.
    Singh S, Sharma D, Suri D, Gupta A, Rawat A, Rohit MK.
    Clin Exp Rheumatol; 2016 Oct 02; 34(3 Suppl 97):S134-8. PubMed ID: 27086575
    [Abstract] [Full Text] [Related]

  • 6. Analysis of biomarker serum levels in IVIG and infliximab refractory Kawasaki disease patients.
    Hachiya A, Kobayashi N, Matsuzaki S, Takeuchi Y, Akazawa Y, Shigemura T, Motoki N, Masumoto J, Agematsu K.
    Clin Rheumatol; 2018 Jul 02; 37(7):1937-1943. PubMed ID: 29302828
    [Abstract] [Full Text] [Related]

  • 7. Infliximab regulates monocytes and regulatory T cells in Kawasaki disease.
    Koizumi K, Hoshiai M, Katsumata N, Toda T, Kise H, Hasebe Y, Kono Y, Sunaga Y, Yoshizawa M, Watanabe A, Kagami K, Abe M, Sugita K.
    Pediatr Int; 2018 Sep 02; 60(9):796-802. PubMed ID: 29543362
    [Abstract] [Full Text] [Related]

  • 8. Medium-Term Complications Associated With Coronary Artery Aneurysms After Kawasaki Disease: A Study From the International Kawasaki Disease Registry.
    McCrindle BW, Manlhiot C, Newburger JW, Harahsheh AS, Giglia TM, Dallaire F, Friedman K, Low T, Runeckles K, Mathew M, Mackie AS, Choueiter NF, Jone PN, Kutty S, Yetman AT, Raghuveer G, Pahl E, Norozi K, McHugh KE, Li JS, De Ferranti SD, Dahdah N, International Kawasaki Disease Registry *.
    J Am Heart Assoc; 2020 Aug 04; 9(15):e016440. PubMed ID: 32750313
    [Abstract] [Full Text] [Related]

  • 9. Infliximab for the Treatment of Refractory Kawasaki Disease: A Nationwide Survey in Japan.
    Masuda H, Kobayashi T, Hachiya A, Nakashima Y, Shimizu H, Nozawa T, Ogihara Y, Ito S, Takatsuki S, Katsumata N, Suzuki Y, Takenaka S, Hirono K, Kobayashi T, Suzuki H, Suganuma E, Takahashi K, Saji T, Committee of Survey on Infliximab use for Kawasaki diseaseJapan Society of Kawasaki Disease, Tokyo, Japan..
    J Pediatr; 2018 Apr 04; 195():115-120.e3. PubMed ID: 29224935
    [Abstract] [Full Text] [Related]

  • 10. Association of Severity of Coronary Artery Aneurysms in Patients With Kawasaki Disease and Risk of Later Coronary Events.
    Miura M, Kobayashi T, Kaneko T, Ayusawa M, Fukazawa R, Fukushima N, Fuse S, Hamaoka K, Hirono K, Kato T, Mitani Y, Sato S, Shimoyama S, Shiono J, Suda K, Suzuki H, Maeda J, Waki K, The Z-score Project 2nd Stage Study Group, Kato H, Saji T, Yamagishi H, Ozeki A, Tomotsune M, Yoshida M, Akazawa Y, Aso K, Doi S, Fukasawa Y, Furuno K, Hayabuchi Y, Hayashi M, Honda T, Horita N, Ikeda K, Ishii M, Iwashima S, Kamada M, Kaneko M, Katyama H, Kawamura Y, Kitagawa A, Komori A, Kuraishi K, Masuda H, Matsuda S, Matsuzaki S, Mii S, Miyamoto T, Moritou Y, Motoki N, Nagumo K, Nakamura T, Nishihara E, Nomura Y, Ogata S, Ohashi H, Okumura K, Omori D, Sano T, Suganuma E, Takahashi T, Takatsuki S, Takeda A, Terai M, Toyono M, Watanabe K, Watanabe M, Yamamoto M, Yamamura K.
    JAMA Pediatr; 2018 May 07; 172(5):e180030. PubMed ID: 29507955
    [Abstract] [Full Text] [Related]

  • 11. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
    Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, Kanegaye JT, Kovalchin JP, Printz BF, Ramilo O, Burns JC.
    Lancet; 2014 May 17; 383(9930):1731-8. PubMed ID: 24572997
    [Abstract] [Full Text] [Related]

  • 12. Regression effect of renin-angiotensin-aldosterone system inhibitors on Kawasaki disease patients with coronary artery aneurysm: a prospective, observational study.
    Suganuma E, Miura M, Koyama Y, Kobayashi T, Kaneko T, Hokosaki T, Numano F, Furuno K, Shiono J, Fuse S, Fukazawa R, Mitani Y.
    Eur J Pediatr; 2024 Nov 17; 183(11):4817-4825. PubMed ID: 39240388
    [Abstract] [Full Text] [Related]

  • 13. Risk factors associated with progression and persistence of small- and medium-sized coronary artery aneurysms in Kawasaki disease: a prospective cohort study.
    Liu L, Luo C, Hua Y, Wu M, Shao S, Liu X, Zhou K, Wang C.
    Eur J Pediatr; 2020 Jun 17; 179(6):891-900. PubMed ID: 31980953
    [Abstract] [Full Text] [Related]

  • 14. Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for Progressive Disease and Adverse Cardiac Events in the US Population.
    Friedman KG, Gauvreau K, Hamaoka-Okamoto A, Tang A, Berry E, Tremoulet AH, Mahavadi VS, Baker A, deFerranti SD, Fulton DR, Burns JC, Newburger JW.
    J Am Heart Assoc; 2016 Sep 15; 5(9):. PubMed ID: 27633390
    [Abstract] [Full Text] [Related]

  • 15. [Kawasaki disease in children--9 years experience].
    Kowalczyk M, Kawalec W, Daszkowska-York J, Turska-Kmieć A, Brzezińska-Rajszys G, Sobielarska D, Ziółkowska L, Kościesza A, Jagiełłowicz D, Mirecka-Rola A.
    Med Wieku Rozwoj; 2005 Sep 15; 9(2):179-93. PubMed ID: 16085959
    [Abstract] [Full Text] [Related]

  • 16. Etiology and prognosis of non-Kawasaki disease induced coronary aneurysms in children: a retrospective case series study.
    Lin Y, Qi H, Liu Y, Wu H, Li Y, Shi L.
    Eur J Pediatr; 2024 Oct 15; 183(10):4229-4234. PubMed ID: 38990385
    [Abstract] [Full Text] [Related]

  • 17. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
    Jone PN, Anderson MS, Mulvahill MJ, Heizer H, Glodé MP, Dominguez SR.
    Pediatr Infect Dis J; 2018 Oct 15; 37(10):976-980. PubMed ID: 29461447
    [Abstract] [Full Text] [Related]

  • 18. Coronary artery aneurysm regression after Kawasaki disease and associated risk factors: a 3-year follow-up study in East China.
    Tang Y, Yan W, Sun L, Xu Q, Ding Y, Lv H.
    Clin Rheumatol; 2018 Jul 15; 37(7):1945-1951. PubMed ID: 29330741
    [Abstract] [Full Text] [Related]

  • 19. The Harada score in the US population of children with Kawasaki disease.
    Tewelde H, Yoon J, Van Ittersum W, Worley S, Preminger T, Goldfarb J.
    Hosp Pediatr; 2014 Jul 15; 4(4):233-8. PubMed ID: 24986993
    [Abstract] [Full Text] [Related]

  • 20. Primary adjunctive corticosteroid therapy is associated with improved outcomes for patients with Kawasaki disease with coronary artery aneurysms at diagnosis.
    Friedman KG, Gauvreau K, Baker A, Son MB, Sundel R, Dionne A, Giorgio T, De Ferranti S, Newburger JW.
    Arch Dis Child; 2021 Mar 15; 106(3):247-252. PubMed ID: 32943389
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.